Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ClinicalTrials.gov ID

NCT07245394

Lead Sponsor

TIDHI Innovation Inc.OTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

200Estimated

Last Update Posted

Aug 31, 2026Actual

Start Date

Jan 29, 2026Actual

Primary Completion Date

Nov 1, 2027Estimated

Completion Date

Nov 1, 2028Estimated

Official Title

SHIFT-IBD: Switching to High-efficacy Anti-IL-23 Guselkumab in Ustekinumab-exposed Persons With Active IBD

Brief Summary

The SHIFT-IBD Study is being conducted at multiple medical centers across Canada to evaluate how well guselkumab (Tremfya) works for people with inflammatory bowel disease (IBD) who haven't responded well enough to ustekinumab.

Patients will begin guselkumab based on their doctor's decision. If eligible, they may be invited to participate in the study, which involves monitoring symptoms, test results, and overall health over the course of one year.

Guselkumab will be given according to local medical guidelines. Doctors can adjust the treatment as needed, just like in routine care.

Researchers believe that switching to guselkumab may be as effective as other advanced treatments. For those who saw some improvement on ustekinumab but not enough, guselkumab may offer better symptom control-without worsening results on medical tests like endoscopy.

The goal is to explore better treatment options for people whose IBD has not been well controlled with current therapies.

• Inflammatory Bowel Disease (IBD)
• Crohn Disease (CD)
• Ulcerative Colitis (UC)
• IBD-unclassified (IBD-U)

• Guselkumab (Tremfya)

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Subjects of any gender aged ≥ 18.

• Confirmed diagnosis of IBD (CD, UC, or IBDU) for at least 6 months prior to baseline visit. Subjects with IBDU will be grouped with subjects with UC. The CD proportion of patients will be capped at 75%.

• Subjects have received ustekinumab for at least 14 weeks and who are currently on or recently discontinued ustekinumab therapy.

• For subjects that have recently discontinued ustekinumab, the last dose of ustekinumab must have been within 12 weeks before Week 0, and no other advanced therapy (i.e., infliximab, adalimumab, golimumab, certolizumab pegol, vedolizumab, natalizumab, risankizumab, mirikizumab, tofacitinib, upadacitinib, ozanimod, etrasimod) was started since stopping ustekinumab.

• Subjects with an inadequate response to ustekinumab who require a change in advanced therapy and are initiating guselkumab, as determined by the treating physician.

• For subjects on off-label ustekinumab dosing (90 mg every 4 or 6 weeks (off-label dosing), enrollment will be capped at 60%.

• Ability and willingness to give written informed consent and comply with the requirements of this study protocol.

• Subjects who have evidence of ongoing endoscopic evidence of disease activity within 3 months prior to Week 0, defined as:

  • For Crohn's Disease: Colonoscopy showing SES-CD score (excluding the presence of narrowing component) of ≥6 (or ≥4 for participants with isolated ileal disease), OR presence of ulcers larger than 5 mm in any segment.
  • For Ulcerative Colitis: Colonoscopy showing Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score ≥4, OR presence of erosions or ulcers in any segment.

Exclusion Criteria:

• History of prior exposure to any anti-p19 inhibitor (risankizumab or mirikizumab).
• Subjects with formal contraindication to guselkumab per the drug label.
• Use of guselkumab for an off-label indication, dosing regimen, or route of administration. Subjects who did not receive guselkumab induction will be excluded.
• Subjects with an ostomy or ileo-anal pouch.
• Subjects with a history of bowel surgery within 6 months prior to Week 0.
• Subjects displaying clinical signs of acute severe UC, fulminant colitis or toxic megacolon within 3 months prior to Week 0.
• Subjects who are expected to require bowel surgery by their IBD physician within the year of enrollment.
• Subjects on 1 or more concomitant biologics.
• Subjects with a history of colonic dysplasia (low-grade dysplasia, high-grade dysplasia, or colorectal cancer). Note: Patients with a history of indefinite for dysplasia would be eligible.
• Subjects with formal contraindication or unwilling to undergo lower endoscopy.
• The patient is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

TIDHI Innovation Inc.OTHER

Collaborators

Janssen Inc.INDUSTRY

mamacmil@me.com(506)454-6682

anushak@barriegi.ca705-721-3344 ext. 155

nausheen.afroz@wgtaresearch.com905-823-0223 ext. 111

alanacarter01@gmail.com905-723-8551 ext. 5444

• A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)

  NCT07310095

  RecruitingInterventionalPhase 4Updated Aug 27, 2026
• Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study

  NCT07616687

  RecruitingInterventionalPhase 4Updated Jun 30, 2026
• A Prospective Observational Study on the Efficacy and Safety of Guselkumab in the Treatment of Crohn's Disease Patients Previously Treated With Ustekinumab

  NCT07487480

  RecruitingObservationalUpdated Mar 23, 2026
• A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)

  NCT07487311

  RecruitingObservationalUpdated Mar 23, 2026
• A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

  NCT07449234

  TerminatedObservationalUpdated Jul 27, 2026
• Ultrasound and Proteomics for Guselkumab Response Assessment in Crohn's Disease (UPGRADE).

  NCT07246460

  RecruitingObservationalUpdated Nov 24, 2025